Advances in Lafora Disease and Related Polyglucosan Disorders Therapy: From Drug Repurposing to Gene-Based Approaches
Lafora disease (LD) is a fatal progressive myoclonus epilepsy caused by biallelic pathogenic variants in EPM2A or NHLRC1, resulting in the accumulation of poorly branched, insoluble glycogen aggregates known as Lafora bodies (LBs). Over the past decade, advances in understanding LD pathogenesis have progressively redefined the role of abnormal glycogen metabolism and highlighted the central contribution of polyglucosan accumulation to disease pathogenesis. These mechanistic insights have substantially changed the therapeutic perspective, shifting the focus from symptomatic management toward interventions aimed at modifying the underlying disease processes. This review provides an updated overview of therapeutic advances reported between 2022 and 2026, with a primary focus on LD while highlighting selected developments in the related polyglucosan disorders Adult Polyglucosan Body Disease and Glycogen Storage Disease type IV. Despite major challenges remaining, recent progress provides a rapidly evolving framework for the development of disease-modifying treatments for LD and offers relevant insights into the broader therapeutic potential and limitations of targeting pathological glycogen in polyglucosan disorders.
Authors
- Marco Salvatore (ORCID: https://orcid.org/0000-0001-6402-2610)
- Paola Torreri (ORCID: https://orcid.org/0000-0002-0488-956X)
- Giorgia Buoncuore (ORCID: https://orcid.org/0009-0009-8630-5676)
- Benedetta Salvucci (ORCID: https://orcid.org/0000-0001-8765-4928)
Institutions
- Istituto Superiore di Sanità (IT)
Publication Details
- Journal
- Journal of Pharmaceutical and BioTech Industry
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3390/jpbi3040029
- Primary Topic
- Glycogen Storage Diseases and Myoclonus
- Type
- article
- Field-Weighted Citation Impact
- 0.00